NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis $7.65 +0.14 (+1.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.47▼$7.7350-Day Range$5.51▼$7.5152-Week Range$5.26▼$9.43Volume483,592 shsAverage Volume550,986 shsMarket Capitalization$306.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get AngioDynamics alerts: Email Address AngioDynamics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside60.1% Upside$12.25 Price TargetShort InterestHealthy4.22% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.87Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.41) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.64 out of 5 starsMedical Sector81st out of 936 stocksSurgical & Medical Instruments Industry13th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 2 research reports in the past 90 days.Read more about AngioDynamics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.22% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 5.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 3.8 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for AngioDynamics this week, compared to 3 articles on an average week.Search Interest11 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows3 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AngioDynamics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.41) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AngioDynamics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About AngioDynamics Stock (NASDAQ:ANGO)AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.Read More ANGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANGO Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comWhen Will AngioDynamics, Inc. (NASDAQ:ANGO) Breakeven?July 19, 2024 | msn.comAngioDynamics, Inc. (NASDAQ:ANGO) Q4 2024 Earnings Call TranscriptJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 19, 2024 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPSJuly 19, 2024 | americanbankingnews.comAngioDynamics, Inc. to Post Q1 2025 Earnings of ($0.13) Per Share, HC Wainwright Forecasts (NASDAQ:ANGO)July 18, 2024 | americanbankingnews.comCanaccord Genuity Group Trims AngioDynamics (NASDAQ:ANGO) Target Price to $13.00July 17, 2024 | americanbankingnews.comAngioDynamics' (ANGO) "Buy" Rating Reaffirmed at HC WainwrightJuly 17, 2024 | americanbankingnews.comAngioDynamics, Inc. (NASDAQ:ANGO) Short Interest UpdateJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 16, 2024 | benzinga.comMedical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual GuidanceJuly 16, 2024 | investorplace.comANGO Stock Earnings: AngioDynamics Beats EPS, Beats Revenue for Q4 2024July 16, 2024 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Updates FY25 Earnings GuidanceJuly 16, 2024 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Issues FY 2025 Earnings GuidanceMay 29, 2024 | bizjournals.comAngioDynamics CEO on what's next after outsourcing moveMay 22, 2024 | markets.businessinsider.comBuy Rating on AngioDynamics: Growth and Regulatory Approvals Underscore Positive OutlookMay 22, 2024 | finance.yahoo.comInvestors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three yearsMay 22, 2024 | markets.businessinsider.comANGO : AlphaVac F1885 Secures CE Mark For Non-Surgical Pulmonary Embolism Treatment In EuropeMay 21, 2024 | businesswire.comAngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ SystemSee More Headlines Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/16/2024Today7/26/2024Next Earnings (Estimated)10/02/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees760Year Founded1988Price Target and Rating Average Stock Price Target$12.25 High Stock Price Target$14.00 Low Stock Price Target$10.00 Potential Upside/Downside+60.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,350,000.00 Net Margins-61.55% Pretax Margin-63.06% Return on Equity-4.91% Return on Assets-3.76% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio1.46 Sales & Book Value Annual Sales$303.91 million Price / Sales1.01 Cash Flow$4.47 per share Price / Cash Flow1.71 Book Value$5.13 per share Price / Book1.49Miscellaneous Outstanding Shares40,060,000Free Float38,012,000Market Cap$306.46 million OptionableOptionable Beta0.66 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. James C. Clemmer (Age 60)CEO, President & Director Comp: $982.92kMr. Stephen A. Trowbridge (Age 50)Executive VP & CFO Comp: $528.02kMr. Chad T. Campbell (Age 53)Senior VP and GM of Global Vascular Access & Oncology Global Business Unit Comp: $416.51kMs. Laura Piccinini (Age 55)Senior VP & GM of International Comp: $444.31kMr. Saleem M. CheeksVice President of CommunicationsMr. Benjamin H. Davis (Age 60)Senior Vice President of Business Development Ms. Marna I. Bronfen-Moore (Age 57)Senior Vice President of Human Resources Mr. Warren G. Nighan (Age 55)Senior Vice President of Quality & Regulatory Affairs Comp: $622.11kMs. Kim L. Seabury (Age 57)Senior Vice President of Information Technology Mr. Juan Carlos SernaSenior Vice President of Scientific & Clinical AffairsMore ExecutivesKey CompetitorsSeaSpineNASDAQ:SPNEAnika TherapeuticsNASDAQ:ANIKCytosorbentsNASDAQ:CTSOIntersect ENTNASDAQ:XENTAntares PharmaNASDAQ:ATRSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,412 shares on 7/26/2024Ownership: 0.436%Allspring Global Investments Holdings LLCSold 1,440 shares on 7/26/2024Ownership: 0.015%Assenagon Asset Management S.A.Sold 414,723 shares on 7/18/2024Ownership: 0.990%Dynamic Advisor Solutions LLCSold 15,080 shares on 7/15/2024Ownership: 0.111%Williams & Novak LLCBought 21,550 shares on 7/12/2024Ownership: 0.111%View All Insider TransactionsView All Institutional Transactions ANGO Stock Analysis - Frequently Asked Questions How have ANGO shares performed this year? AngioDynamics' stock was trading at $7.84 on January 1st, 2024. Since then, ANGO stock has decreased by 2.4% and is now trading at $7.65. View the best growth stocks for 2024 here. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings data on Tuesday, July, 16th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.11. The business's revenue for the quarter was down 22.1% compared to the same quarter last year. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. Does AngioDynamics have any subsidiaries? AngioDynamics subsidiaries include these companies: Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and others. Who are AngioDynamics' major shareholders? AngioDynamics' top institutional investors include Assenagon Asset Management S.A. (0.99%), Bank of New York Mellon Corp (0.44%), Dynamic Advisor Solutions LLC (0.11%) and Williams & Novak LLC (0.11%). Insiders that own company stock include James C Clemmer, James C Clemmer, Stephen A Trowbridge, Wesley Johnson, Dave Helsel, Scott Centea and Chad Thomas Campbell. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL). This page (NASDAQ:ANGO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
